Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 38, n° 1
pages 49-55 (janvier 1998)
Doi : 10.1016/S0190-9622(98)70538-9
Patterns of X chromosome inactivation in sporadic basal cell carcinomas: Evidence for clonality
 

Douglas S. Walsh, MC, MAJ, USA, a,*, Monica Peacocke, MDb, Allan Harrington, MC, MAJ, USAa, William D. James, MDa,**, Hui C. Tsou, MDb
Washington, D.C., and New York, New York 

Abstract

Background: Some basal cell carcinomas (BCCs) contain genetic mutations, suggesting that the lesion is composed of a monoclonal population of cells. Clonality, a distinguishing feature of neoplasia, can be inferred by referencing clonal markers such as the pattern of X chromosome inactivation. The X-linked human androgen receptor gene (HUMARA; GenBank) contains a polymorphic DNA marker that reliably illustrates the pattern of X chromosome inactivation in a tissue. Objective: Our purpose was to determine the clonality of sporadic BCCs by examining patterns of X chromosome inactivation. Methods: The patterns of X chromosome inactivation in paired samples of normal skin and sporadic BCCs from 24 women were compared by means of the HUMARA gene assay. Results: All samples from normal skin displayed random X chromosome inactivation, consistent with lyonization. In 15 of 25 tumor samples (60%), nonrandom X chromosome inactivation was detected, consistent with monoclonality. Conclusion: At least some sporadic BCCs are composed of a monoclonal population of cells, strengthening the contention that a collection of mutations confers a growth advantage to this epithelial lesion. (J Am Acad Dermatol 1998;38:49-55.)

The full text of this article is available in PDF format.

 From the Dermatology Services, Walter Reed Army Medical Center, Washington, a and Columbia-Presbyterian Medical Center, New York.b
 Supported by the Department of Clinical Investigation, Walter Reed Army Medical Center, the Walter Reed Army Institute of Research Medical Research Fellowship Program, and by grants from the National Skin Cancer Foundation (1994 Frederick H. Mohs Award to D. S. W.), the Dermatology Foundation (1995 Leon M. Ariyan Research Grant, Ortho Pharmaceutical Corporation to D. S. W), the National Institutes of Health (AG-9927) (to M. P.), and the American Institute for Cancer Research (to M. P.).
 The opinions expressed herein reflect the private views of the authors and do not purport to represent the views of the Department of the Army or the Department of Defense.
 Reprint requests: MAJ Douglas S. Walsh, MC, USA, AFRIMS, APO, AP 96546-5000 USA.
 *Current address: Department of Immunology and Medicine, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand (Correspondence: AFRIMS, APO, AP 96546-5000 USA).
♢♢ **Current address: Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104.
 16/1/85757



© 1998  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline